Explore Our Areas

Latest News

Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

FLORENCE, Italy and NEW YORK, NY, August 11, 2022 -- The Menarini Group (“Menarini”), a privately held Italian pharmaceutical and diagnostics company, and Stemline...

ATGC Co., Ltd. License Agreement Grants RELIFE S.r.l. Exclusive Rights to Register, Promote, Distribute, and Market the Novel Botulinum Toxin Type A (ATGC-100) in Europe and the United Kingdom.

ATGC Co., Ltd. (Jang, Sungsu, CEO of ATGC), a biopharmaceutical research and development company, has signed a strategic partnership, license and supply agreement with RELIFE S.r.l...

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

PHILADELPHIA, PA and FLORENCE, Italy— August 02, 2022—Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology...

Search Menarini in the world

v

Etiam commodo dui eget wisi. Donec iaculis gravida nulla. Donec quis nibh at felis congue commodo. Etiam bibendum elit eget erat.

Use the key combination "ctrl" + "mouse wheel" or the "+" and "-" buttons at the bottom right to browse the map



menarini for people

Discover our responsibility projects to stand close to people

read more

Follow our blog

Discover our stories from all over the world

Read More

fondazione internazionale menarini

a meeting point for all friends with common ideals towards the progress of sciences for the benefit of mankind.

sergio gorini, foundation’s first president

read more